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Abstract
Goldberg–Shprintzen syndrome (GOSHS) is caused by loss of function variants in
the kinesin binding protein gene (KIFBP). However, the phenotypic range of this
syndrome is wide, indicating that other factors may play a role. To date, 37 patients
with GOSHS have been reported. Here, we document nine new patients with var-
iants in KIFBP: seven with nonsense variants and two with missense variants. To our
knowledge, this is the first time that missense variants have been reported in
GOSHS. We functionally investigated the effect of the variants identified, in an
attempt to find a genotype–phenotype correlation. We also determined whether
common Hirschsprung disease (HSCR)‐associated single nucleotide polymorphisms
(SNPs), could explain the presence of HSCR in GOSHS. Our results showed that the
missense variants led to reduced expression of KIFBP, while the truncating variants
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resulted in lack of protein. However, no correlation was found between the severity
of GOSHS and the location of the variants. We were also unable to find a corre-
lation between common HSCR‐associated SNPs, and HSCR development in GOSHS.
In conclusion, we show that reduced, as well as lack of KIFBP expression can lead to
GOSHS, and our results suggest that a threshold expression of KIFBP may modulate
phenotypic variability of the disease.
K E YWORD S
GOSHS, HSCR, KIAA1279, KIFBP, missense variants
1 | INTRODUCTION
Goldberg–Shprintzen syndrome (GOSHS; MIM# 609460) is a rare and
severe autosomal recessive disorder, characterized by moderate in-
tellectual disability, dysmorphic facial features (arched eyebrows, dense
eyelashes, broad nasal bridge, hypertelorism, synophrys, ptosis, large
ears, and a prominent long nose), microcephaly (head circumference
< ‐2.5 SD), and axonal neuropathy. GOSHS was first described by
Goldberg and Shprintzen in 1981, and to date, 37 cases have been
reported through clinical diagnosis, with variable severities and addi-
tional features, such as iris coloboma, cleft palate/bifid uvula, corneal
ulcers, and congenital heart defects (Breslau and Laan, 1989; Brooks,
2005; Brooks et al., 1999; Brooks et al., 2005; Brunoni, Joffe, Farah, &
Cunha, 1983; Bruno et al., 2011; Dafsari et al., 2015; Drévillon et al.,
2013; Fryer, 1998; Goldberg & Shprintzen, 1981; Halal & Morel, 1990;
Hurst, Markiewicz, Kumar, & Brett, 1988; Kumasaka & Clarren, 1988;
Silengo et al., 2003; Ohnuma, Imaizumi, Masuno, Nakamura, & Kuroki,
1997; Murphy, Carver, Brooks, Kenny, & Ellis, 2006; Salehpour,
Hashemi‐Gorji, Soltani, Ghafouri‐Fard, & Miryounesi, 2017; Tanaka, Ito,
Cho, & Mikawa, 1993; Valence et al., 2013; Yomo, Taira, & Kondo,
1991). Homozygosity mapping followed by Sanger sequencing, identi-
fied homozygous or compound heterozygous loss of function (LOF)
variants in the kinesin binding protein gene (KIFBP, previously known as
KIAA1279), as causative for GOSHS (Brooks et al., 2005; Dafsari et al.,
2015; Valence et al., 2013). Twenty‐five out of the 37 reported cases
have been shown to have truncating variants in this gene (Brooks,
2005; Brooks et al., 1999; Brooks et al., 2005; Bruno et al., 2011;
Dafsari et al., 2015; Drévillon et al., 2013; Goldberg & Shprintzen, 1981;
Hurst et al., 1988; Murphy et al., 2006; Salehpour et al., 2017; Valence
et al., 2013). KIFBP is expressed throughout the developing embryo at
early stages of development and becomes highly expressed in the
central and peripheral nervous systems at later developmental stages
(Alves et al., 2010). KIFBP is 621 amino acids long and contains two
tetratricopeptide repeats. It is involved in the axonal structure and
outgrowth, microtubule dynamics, and cargo trafficking, functioning by
binding with various microtubule‐associated proteins, such as kinesins
and the superior cervical ganglia 10 (SCG10; Alves et al., 2010;
Kevenaar et al., 2016; Lyons, Naylor, Mercurio, Dominguez, & Talbot,
2008; Wozniak, Melzer, Dorner, Haring, & Lammers, 2005). However,
the location of the binding domains of KIFBP remains unmapped, and
its precise function is unknown. In mice, inactivation of Kifbp is lethal,
leading to central and peripheral nervous system defects and delayed
enteric nervous system development (Hirst et al., 2017). Similarly,
knocking out the KIFBP orthologue in zebrafish led to a disruption of
axonal structure and outgrowth, including axonal defects in the enteric
nervous system (Lyons et al., 2008).
Hirschsprung disease (HSCR) is reported in ~70% of patients
with GOSHS, but is considered to be a variable feature. HSCR is
characterized by the absence of enteric ganglia in the distal colon
and occurs in multiple defined syndromes (Amiel et al., 2008). The
link between GOSHS and HSCR is poorly understood, especially
considering the variability of its presence, even between family
members sharing the same pathogenic variant. It is suspected that a
balance of protective and/or predisposing factors in the (epi)genome
influences HSCR development (Brosens et al., 2016; Chatterjee et al.,
2016; Emison et al., 2005; Kapoor et al., 2015). Common variants in
the Rearranged during transfection gene (RET), the Semaphorin 3A
gene (SEMA3A), and the Neuregulin 1 gene (NRG1) are known to be
associated with HSCR risk. Previous studies have already in-
vestigated the effect of common variants located in intron 1 of RET in
a series of patients diagnosed with a Mendelian syndrome where
HSCR is part of the phenotype (de Pontual et al., 2006, 2007).
However, no such study has been performed yet for GOSHS.
Here, we provide an update of all KIFBP reported cases and add
nine unpublished cases with six new KIFBP variants, three of which are
missense. This is the first time that missense variants have been re-
ported to play a role in GOSHS. Whether these missense variants also
result in LOF is unknown. Therefore, we functionally tested the effect
of these variants, on KIFBP expression levels and cellular localization.
We also investigated if the truncating variants described, result in loss
of protein. Finally, we determined if the occurrence of HSCR in GOSHS
can be explained by the presence of common modifier alleles.
2 | MATERIALS AND METHODS
2.1 | Patient inclusion
In this study, nine new patients were included (Table 1). These patients
were seen routinely in hospitals in the UK, Ireland, Norway, Poland,
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TABLE 1 All published and unpublished patients with KIFBP variants and their clinical features (ENST00000361983.7)
Code US1 US2 Case1 Case2 BP1 BP2 V‐4 V‐6 V‐9
Sex M F M M F F M F M
KIFBP variant c.1551‐
1552insA
c.1551‐
1552insA
c.250G>T c.250G>T c.250G>T c.250G>T c.268C>T c.268C>T c.268C>T
Protein p. Gln518
Asnf*11
p. Gln518
Asnf*11
p. Glu84* p. Glu84* p. Glu84* p. Glu84* p. Arg90* p. Arg90* p. Arg90*
HSCR + + + + + − + + −
Facial dysmorphism + + + + + + + + +
Microcephaly + + + + + + − + +
Brain malformation + + + + + + + + +
Developmental delay + + + + + + + + +
Seizures + − − − − − − − −
Neuropathy ? ? ? ? ? ? ? ? ?
Short stature + + + + + + ? + +
Hypotonia + + ? ? ? ? ? ? +
Eye anomalies
(coloboma, ptosis,
hyperopia;
megalocornea)
+ + + + + + ? + +
Cardiac anomalies
(ventricular septal
defects, aortic valve
incompetence)
− − − − − − ? − −
Skeletal anomalies
(oligodontia,
scoliosis)
+ + + − − − + + −
OFC centile <2nd centile <2nd centile <3rd centile <3rd centile 3rd centile ? 3rd centile 3rd centile <3rd centile
Ref Goldberg and
Shprintzen
(1981)
Goldberg and
Shprintzen
(1981)
Hurst
et al. (1988)
Hurst
et al. (1988)
Hurst
et al. (1988)
Brooks
(2005)
Brooks
et al. (1999)
Brooks
et al. (1999)
Brooks
et al. (1999)
Code VI‐1 VI‐3 CYP1 CYP2 UK1 UK2 AU1 IV‐2 IV‐1
Sex F F M F M M F M M
KIFBP variant c.268C>T c.268C>T c.718G>T c.718G>T c.1117‐
1118insA
c.1117‐
1118insA
c.1397dupA c.268C>T c.599C>A
Protein p. Arg90* p. Arg90* p. Glu240* p. Glu240* p. Ala373
Asnf*17
p. Ala373
Asnf*17
p. Tyr466* p. Arg90* p. Ser200*
HSCR + + + − + + + + +
Facial dysmorphism + + + + + + + + +
Microcephaly + + + + + + + +
Brain malformation + + + + + + + + +
Developmental delay + + ? ? + + + + +
Seizures − − − − + − ? ? ?
Neuropathy ? ? ? ? ? ? ? ? ?
Short stature + ? ? ? ? ? + ? ?
Hypotonia + ? + + + + ? ? ?
Eye anomalies
(coloboma, ptosis,
hyperopia;
megalocornea)
? ? ? ? − − − + +
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TABLE 1 (Continued)
Code VI‐1 VI‐3 CYP1 CYP2 UK1 UK2 AU1 IV‐2 IV‐1
Sex F F M F M M F M M
Cardiac anomalies
(ventricular septal
defects, aortic valve
incompetence)
− ? ? ? − − − − +
Skeletal anomalies
(oligodontia,
scoliosis)
+ ? − + + + − − +
OFC centile 3rd centile ? <3rd centile ? <3rd centile <3rd
centile
? ? ?
Ref Brooks
et al. (1999)
Brooks
et al. (2005)
Brooks
(2005)
Brooks
(2005)
Murphy
et al. (2006)
Murphy
et al.
(2006)
Bruno
et al. (2011)
Drévillon
et al. (2013)
Drévillon
et al. (2013)
Code IV‐3 IV‐1.2 V‐2 IV.5 IV.8 UK7 IRN1 IE1 UK3
Sex M F F F F F M F M
KIFBP variant c.599C>A c.604_605
delAG
c.604_605d-
elAG
Deletion exon
2 & 3
Deletion exon
2 & 3
Deletion
exon 5 & 6
c.976C>T c.1694_169-
5 delAG
Deletion
exon 6
Protein p. Ser200* p. Arg202
Ilefs*2
p. Arg202
Ilefs*2
p. Asn143fsX1 p. Asn143fsX1 − p. Gln326* p. Glu565
AsnfX15
−
HSCR + − + − ? + + + +
Facial dysmorphism + + + + − + + + +
Microcephaly + + + + + + + + +
Brain malformation + + + + + + + + +
Developmental delay + + + + + + + + +
Seizures ? ? ? ? ? − + ? −
Neuropathy ? ? ? ? ? + ? ? +
Short stature ? ? ? ? ? + + ? +
Hypotonia ? ? ? ? ? + + + ?
Eye anomalies
(coloboma, ptosis,
hyperopia;
megalocornea)
+ − − ? ? + + + +
Cardiac anomalies
(ventricular septal
defects, aortic valve
incompetence)
− − + ? ? + − + −
Skeletal anomalies
(oligodontia,
scoliosis)
+ − − ? ? + − − +
OFC centile ? ? ? 3rd centile 3rd centile <0.4th
centile
normal ? <0.4th
centile
Ref Drévillon
et al. (2013)
Drévillon
et al. (2013)
Drévillon
et al. (2013)
Valence
et al. (2013)
Valence
et al. (2013)
Dafsari
et al.
(2015)
Salehpour
et al. (2017)
This paper This paper
Code UK4 PL1 PL2 NO1 NO2 CYP3 NL1
Sex F M M F M F M
KIFBP variant Deletion
exon 6
c.1516dupA c.1516dupA Deletion
exon 5&6
Deletion
exon 5&6
c. 565C>T c.68A>G;
c.1279A>G
Protein − p. Ile506
Asnfs*3
p. Ile506Asnfs*3 − − p. Pro189Ser p. Glu23Gly;
p. Ser427Gly
(Continues)
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Australia, The Netherlands, and Cyprus. Eight of the nine patients were
ascertained by clinical diagnosis of GOSHS, followed by molecular
confirmation. The criteria used for the clinical diagnosis relied mainly on
the presence of microcephaly, dysmorphic facial features, and detection
of axonal neuropathy. The presence of HSCR was suspected by the
inability to pass meconium on the first days of life, followed by an
abdominal X‐ray and a contrast enema. Confirmation of the disease was
done by histopathological analysis of a rectal suction biopsy.
Seven patients were genetically screened for KIFBP variants at
the University Medical Centre Groningen, Groningen, NL, to confirm
diagnosis of GOSHS. The two patients carrying missense variants
were screened at the department of Clinical Genetics in the Erasmus
Medical Centre, Rotterdam, NL, and the department of Clinical
Genetics at the Cyprus Institute of Neurology and Genetics, in
Nicosia, Cyprus. Permission to use diagnostic findings for publication
was obtained from all parents.
2.2 | Sequencing
Sanger sequencing of KIFBP was performed for eight of the nine
patients, as previously described (Brooks et al., 2005). A list of pri-
mers is available on request. Patient NL1 was the only one subjected
to whole‐exome sequencing, due to lack of phenotypic features
characteristic of GOSHS. Sequencing data were analyzed using a
filter for neuronal migration abnormalities, leading to the identifi-
cation of two heterozygous missense variants in KIFBP. Both variants
were confirmed by Sanger sequence. All new variants described were
submitted to ClinVAr (http://www.ncbi.nlm.nih.gov/clinvar/).
All patients and parents were also Sanger sequenced for the
presence of selected common HSCR associated polymorphisms in
RET (Chatterjee et al., 2016), NRG1, and SEMA3A Kapoor et al.,
2015). Primers used are listed in Table S1.
2.3 | Expression vectors
The pcDNA–HA–hKIFBP vector was described before (Alves
et al., 2010). When produced from this vector, the KIFBP protein
contains an N‐terminal HA‐tag. The three missense variants
identified were generated by site‐directed mutagenesis on
pcDNA–HA–hKIFBP, according to the manufacturer's instruc-
tions (QuickChange II Site‐directed Mutagenesis Kit, Agilent
Technologies). We used the same vector and procedure to in-
troduce the two frameshifts variants, as well as the two deletions
identified. Sanger sequencing confirmed the presence of all the
TABLE 1 (Continued)
Code UK4 PL1 PL2 NO1 NO2 CYP3 NL1
Sex F M M F M F M
HSCR − + − + − + −
Facial dysmorphism + + + + + + −
Microcephaly + + + + + + +
Brain malformation − − + + + + +
Developmental delay + + + + + + +
Seizures − − − − − − −
Neuropathy ? − − − − + ?
Short stature + + + + + + +
Hypotonia ? − − + + ? ?
Eye anomalies
(coloboma, ptosis,
hyperopia;
megalocornea)
− + + + + + ?
Cardiac anomalies
(ventricular septal
defects, aortic valve
incompetence)
− − − − + − ?
Skeletal anomalies
(oligodontia,
scoliosis)
+ + + − + + ?
OFC centile <0.4th centile <3rd centile <3rd centile <1st centile <1st
centile
<0.4th centile ?
Ref This paper This paper This paper This paper This paper This paper This paper
Abbreviation: HSCR, Hirschsprung disease.
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variants in KIFBP. No additional variants were inserted. Primers
used are listed in Table S1.
2.4 | Cell culture and transfection
Human embryonic kidney cells (HEK293) were cultured in Dulbec-
co's modified Eagle's medium high medium containing 4.5 g/L glu-
cose, L‐glutamine and pyruvate (Gibco), supplemented with 10% fetal
calf serum (Gibco) and 1% penicillin/streptomycin (Gibco). Cells were
incubated at 37°C and 5% CO2. For transient transfection, 3 × 10
5
cells were seeded per well in 6‐well plates. After 24 h, transfection
with expression vectors containing either HA‐tagged wild type or
mutated KIFBP complementary DNA (cDNA) was performed using
GeneJuice® transfection reagent (Millipore), according to the man-
ufacturer's instructions.
2.5 | RNA isolation and q‐PCR
RNA was isolated from HEK293 cells transfected with KIFBP wild‐
type (WT) and mutant constructs, using the RNAeasy Kit (Qiagen),
according to the manufacturer's instructions. cDNA preparation and
quantitative polymerase chain reaction (q‐PCR) were performed, in
triplicate, as previously described (McCann et al., 2019). A list of
primers used can be found in Table S1.
2.6 | Immunofluorescence and confocal
microscopy
Following KIFBP overexpression in HEK293, cells were fixed with
4% paraformaldehyde for 15min, and made permeable with 1%
bovine serum albumin and 0.1% Triton X‐100 in phosphate‐buffered
saline (PBS). Cells were stained for HA using the HA‐Tag antibody
(C29F4, Cell Signaling Technology, USA) at 1:1500 dilution, and the
Cy3 AffiniPure donkey antirabbit IgG, 1:200 dilution (Jackson Im-
munoresearch, UK). Three wells were fixed for each construct. Cells
were imaged on a Leica SP5 confocal microscope.
2.7 | Cell lysates and western blot analysis
Twenty‐four to 48 h after transfection, cells were washed with PBS and
lysed as described before (Alves et al., 2010). Protein quantification was
determined using the Pierce Bicinchoninic Acid Protein Assay kit
(Thermo Fisher Scientific), and 40 μg of cell lysates were stored in
loading buffer at −80°C before they were processed further. Sodium
dodecyl sulfate‐polyacrylamide gel electrophoresis followed by western
blot analysis was performed using an in‐house anti‐HA antibody, and a
GAPDH antibody (Millipore), both at 1:5000 dilution. Secondary anti-
bodies used were the IRDye 680RD goat antimouse and the IRDye
800CW goat antimouse (Li‐Cor), at 1:10,000 dilution.
2.8 | Statistical analysis
All results are presented as the mean ± standard error of the
mean (SEM). All data were analyzed using a two‐tailed Student
t test. p < .05 was considered to be statistically significant.
3 | RESULTS
3.1 | Three novel homozygous truncating variants
in KIFBP were identified in five patients with GOSHS
Seven previously unreported patients with GOSHS, three sibling
pairs and an isolated patient, were sequenced for KIFBP (Table 1).
Large exon deletions, as well as new frameshift variants in KIFBP,
were identified in these patients (Figure 1 and Table 1). All variants
were inherited from healthy parents.
F IGURE 1 Schematic representation of KIFBP highlighting positions of all reported variants. Missense variants are indicated in blue, and
nonsense variants in bold red. Square brackets show exon deletions. Transcript number used: ENST00000361983.7.
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Patient IE1 is a female with a classical GOSHS phenotype and
HSCR. She was found to have a homozygous two base‐pair deletion
at c.1694_1695 (NM_015634.3:c.1694_1695delAG) of KIFBP, caus-
ing a premature stop in Exon 7 (accession number: SCV000994837).
Siblings PL1 and PL2, are both males with classical GOSHS
facial dysmorphism. PL1 has HSCR, where PL2 does not. A
homozygous insertion of an A at position c.1516_1517 of KIFBP
(NM_015634.3:c.1516dupA) was identified in these patients,
leading to the appearance of a premature stop in Exon 7
(Accession number: SCV000994838).
Siblings UK3 and UK4 were found to have a homozygous deletion
of Exon 6 of KIFBP (NM_015634.3:c.875_990del). Patient UK3 is a male,
with classical GOSHS phenotype and HSCR. Patient UK4 is a female
and does not have HSCR (accession number: SCV000994839).
Siblings NO1 and NO2 have a deletion of Exons 5 and 6 of KIFBP
(NM_015634.3:c.790_990del). Both have a classical GOSHS pheno-
type, but NO1, female, has HSCR where it is absent in her brother,
NO2. This deletion is homozygous and has been previously reported
(Dafsari et al., 2015).
According to the guidelines established by the American College
of Medical Genetics (ACMG), all truncating variants identified in our
GOSHS patients are classified as pathogenic (Table S2). These var-
iants are also predicted to result in a total loss of KIFBP expression
(Table 2). However, since there is very little information available on
the effect of frameshifts and nonsense variants on the stability of
KIFBP, we decided to study the effect of these variants, by per-
forming in vitro expression assays. For this, HEK293T cells were
transfected with constructs expressing the WT, and mutant KIFBP
cDNAs. q‐PCR results showed a decrease on the RNA levels for all
mutants analyzed, and no protein expression was detected for any of
them. These results show that the truncating variants here de-
scribed, completely abolish expression of KIFBP (Figure 2a,b).
3.2 | Three missense KIFBP variants were
identified in two patients
The first patient (NL1) is a 10‐year‐old male of Moroccan ancestry, born
to consanguineous parents. He had a history of microcephaly and
presented with short stature. Brain imaging showed pachygyria and he
was affected by demyelinating peripheral neuropathy and perceptive
deafness. However, he lacked the typical facial features of GOSHS, had
no skeletal symptoms, and had no reported gastrointestinal or enteric
nervous system abnormalities. As GOSHS was initially not considered a
possible diagnosis due to the lack of characteristic features, whole‐
exome sequencing was conducted on DNA from blood collected for
diagnostic purposes. This resulted in the identification of two
heterozygous missense variants in KIFBP, one in Exon 1,
NM_015634.3:c.68A>G (p. Glu23Gly; Mut1; accession number:
SCV000994834), and one in Exon 7, NM_015634.3:c.1279A>G
(p. Ser427Gly; Mut2; accession number: SCV000994835; Figure 1;
Table 1). The variants were inherited from the parents, and have been
previously reported in healthy controls (allele frequency of 0.00223 for T
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Mut1 and 0.0000318 for Mut2 on gnomAD browser). Based on the
ACMG guidelines, both variants were predicted to be likely benign (-
Table S2). However, according to different prediction tools, Polyphen‐2,
SIFT, and conservation scores there seems to be evidence to support a
deleterious effect on the gene (Table 2). No other likely pathogenic
variants were identified in this patient.
The second patient (CYP3), is a 28‐year‐old female of Cypriot
ancestry, born to reportedly nonconsanguineous parents. She had a
history of microcephaly, mild intellectual disability, and develop-
mental delay. She presented with short stature, typical dysmorphic
facial features with bilateral blepharoptosis, and corneal ulcers. She
was diagnosed with HSCR at the age of 3 years. In addition, she had
scoliosis, lordosis, pes cavus, as well as mild sensory motor neuro-
pathy with both axonal and demyelinating features. Brain magnetic
resonance imaging did not reveal a central nervous system (CNS)
abnormality. No copy number variations were detected with array‐
CGH. Review of the family history revealed that the patient's
younger brother was diagnosed with HSCR and died in the neonatal
period from sepsis, following surgery for meconium ileus. There was
also a report of a maternal relative who apparently died in infancy
and had features suggestive of GOSHS. Sequencing of KIFBP showed
a homozygous missense variant in Exon 3, NM_015634.3:c.565C>T
(p. Pro189Ser; Mut3; accession number: SCV000994836; Figure 1;
Table 1), which was inherited from the parents. This variant has not
been reported before (gnomAD browser), and based on the ACMG
guidelines is classified as pathogenic (Table S2). Prediction tools,
predict this variant as benign (Table 2). However, its CADD score is
17.95, indicating a potentially pathogenic effect.
3.3 | KIFBP expression levels were reduced by the
missense variants
To evaluate the effect of the missense variants, expression levels of
KIFBP were determined after the transfection of HEK293T cells with
constructs expressing the WT and mutant KIFBP cDNA. q‐PCR re-
sults showed significantly decreased RNA levels for all mutants when
compared with the wild‐type (Figure 3a). All mutants also showed a
significantly decreased protein expression of KIFBP, when compared
with WT. But, as expected based on the RNA levels, Mut3 showed
the lowest expression (Figure 3b,c).
3.4 | Cellular localization of KIFBP is unaffected
by the missense variants
Tagged WT and mutant KIFBP constructs were overexpressed in
HEK293 cells, to determine any effect of the variants in the orga-
nization or localization of KIFBP within the cell. The WT protein is
seen to have high cytoplasmic expression, as previously described
(Alves et al., 2010). For the mutant proteins, no effect on KIFBP
localization was observed (Figure 4).
3.5 | Previously associated common SNPs in RET,
NRG1, and SEMA3A do not affect HSCR development
in GOSHS
It is known that phenotypic variability exists in patients with GOSHS
and that HSCR is a variable feature, even within families with the
same KIFBP truncating variant (Table 1). Here, we investigated
whether the presence of previously common SNPs associated with
HSCR, would be the determinant factor for the presence of this
disorder in GOSHS. The SNPs we decided to investigate are located
in intron 1 of RET, SEMA3A, and NRG1. Although, all these SNPS have
been described to increase the risk for HSCR (de Pontual et al., 2006,
2007), we were unable to find a significant correlation between them
and the occurrence of HSCR in this subset of GOSHS patients and
unaffected family members (t test, p = .526; Tables 3 and 4).
4 | DISCUSSION
In this manuscript, we report nine new patients with variants in
KIFBP. A common feature in all these patients is the presence of
intellectual disability and developmental delays. However, the phe-
notypic spectrum is broad, with distinct facial morphology,
F IGURE 2 Expression of KIFBP is lost in the presence of the
frameshifts and nonsense variants identified. (a) q‐PCR results
showing relative normalized expression of KIFBP following
transfection with wild type (WT) or mutant constructs. All mutant
constructs showed a decrease in KIFBP expression compared to WT
levels. (b) Western blot of KIFBP expression following transfection of
either WT or mutant constructs. No KIFBP expression was detected
in any of the mutants. q‐PCR, quantitative polymerase chain
reaction; UT, untransfected
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microcephaly, and other CNS malformations. Interestingly, this wide
phenotypic range is even found in siblings carrying the same variant.
As can be seen in Table 1, the incidence of HSCR in GOSHS is ∼70%
(24/34). Seven out of 10 patients without HSCR, have a family
member carrying the same KIFBP variant, that does have this disease,
suggesting the presence of modifying factors, or the absence of
protective factors in these patients than can tilt the balance in favor
of HSCR. Here, we hypothesized that selected common HSCR
modifier variants in RET (Chatterjee et al., 2016), NRG1, and SEMA3A
(Kapoor et al., 2015) may work as these modifying factors, as it has
been shown for other syndromes (Chatterjee et al., 2016; De Pontual
et al., 2007; Tang et al., 2016). However, our results did not show any
correlation between the incidence of HSCR and the presence of
these common polymorphisms in the cohort analyzed (p = .526,
Table 3). As HSCR is a complex genetic disease, multiple factors are
known to play a role in its development in addition to genetic risk
factors, such as epigenetic changes (Tang et al., 2013), protective
pathways (Griseri et al., 2007), threshold numbers of cells (Barlow,
Wallace, Thapar, & Burns, 2008), or stochastic chance (Cheeseman,
Zhang, Binder, Newgreen, & Landman, 2014). Moreover, since HSCR
is such a common feature in GOSHS, one might argue that its oc-
currence is coupled to the expression levels of KIFBP, or to changes
in the signaling network regulated by this protein. Further research
is therefore required, to investigate which of these hypotheses can
explain the variability of such features.
LOF variants in KIFBP are known to cause GOSHS. However,
there seems to be no correlation between the location of the variant,
and the severity of syndromic characteristics (Figure 1), as they all
seem to result in total loss of protein (Brooks et al., 2005; Drévillon
et al., 2013). In seven of the nine patients reported here, nonsense
variants or frameshifts were identified, resulting in loss of expression
of KIFBP (Figure 2). Unfortunately, we were not able to assess if this
was the result of nonsense mediated decay, as we were not able to
obtain patient fibroblasts. In the remaining two patients, missense
variants were identified. This finding was quite interesting, as no
missense variants have been previously reported in GOSHS. Patient
CYP3 carries a homozygous variant in KIFBP that leads to the amino
acid substitution of proline by a serine. Patient NL1 is compound
heterozygous, and has two different missense mutations in each of
his alleles. One leads to the substitution of glutamate by glycine,
while the other changes a serine into glycine. Based on the chemical
properties of the different amino acids, the most dramatic change is
expected to be the one found in patient CYP3. This is because pro-
line is a nonpolar amino acid that is normally present buried within
the protein core due to its hydrophobic nature, while serine is a
polar, hydrophilic aminoacid, able to form hydrogen bonds. For pa-
tient NL1, although the amino acid changes identified lead to the
substitution of relatively big amino acids, glutamate and serine, by
glycine, the smallest amino acid due to its minimal side chain, they
can basically fit into hydrophilic or hydrophobic environments with
relatively minor consequences. Prediction tools and conservation
scores are shown in Table 2. We showed here that these missense
variants lead to decreased KIF1BP expression, and thus, considered
them to be LOF as well. However, the characteristics and diagnosis
of these two patients differ tremendously. While patient CYP3 has
the hallmark features of GOSHS, including HSCR (Table 1), patient
NL1 does not show any of the clinically defined features of this
syndrome. In fact, the variants in KIBBP were only identified in this
patient after exome sequence, and we cannot exclude that they are
just polymorphisms due to the fact that they have both been found in
the general population. However, our functional results suggest
F IGURE 3 Expression of KIFBP is altered in the presence of the
missense variants. (a) q‐PCR results showing relative normalized
expression of KIFBP following transfection with wild type (WT) or
mutant constructs. All mutant constructs show a decrease in KIFBP
expression compared with WT levels. (b) Western blot of KIFBP
expression following transfection of either WT or mutant constructs.
Decreased KIFBP expression was detected for all mutants.
(c) Quantification of protein expression after normalization for
GAPDH. Mut1, A68G, shows ~70% expression, Mut2, A1279G,
shows ~80% expression, and Mut3, C565T, shows ~25% expression,
when compared with the WT. Error bars show SEM. q‐PCR,
quantitative polymerase chain reaction; SEM, standard error of
mean; UT, untransfected. *p < .05.
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F IGURE 4 Confocal images of KIFBP localization after transfection of HEK293 cells with wild‐type (WT) and mutant constructs, show no
difference between WT and missense variants. (a) WT. (b) Mut1–A68G. (c) Mut2–A1279G. (d) Mut3–C565T
TABLE 3 Influence of common SNPs on the presence of HSCR in GOSHS
RET RET RET RET RET NRG1 NRG1 SEMA3A
# HSCR rs2506030 rs7069590 rs2505998 rs2435357 rs9282834 rs1176600 rs8022714 rs7005606
1 No G/G T/C A/G A/G G/G A/A C/C G/T
2 No G/G T/C A/G A/G G/G A/A C/C T/T
3 No G/G T/C A/G A/G G/G A/A C/C T/T
4 No G/A C/C G/G G/G G/G A/C C/C G/T
5 No G/G T/T A/G A/G G/G A/A C/C G/T
6 No G/A T/C G/G G/G G/G A/A C/C T/T
7 No G/A T/T A/A A/A G/G A/A C/C T/T
8 No A/A T/C G/G G/G G/G A/C C/C G/T
9 No A/A T/T G/G G/G G/G A/A C/C G/T
10 No G/A T/T G/G G/G G/G A/A C/C G/T
11 No G/A T/T G/G G/G G/G A/A C/C T/T
12 No G/A T/T G/G G/G G/G A/A C/C T/T
13 No A/A T/T A/A A/A G/G A/A C/C T/T
14 No A/A T/C A/G A/G G/G C/C C/C T/T
15 Yes G/G T/C A/G A/G G/G A/A C/C G/T
16 Yes G/G T/C A/G A/G G/G A/A C/C G/T
17 Yes G/G T/C A/G A/G G/G A/A C/C T/T
18 Yes G/G T/C A/G A/G G/G A/A C/C G/T
19 Yes G/A T/C A/G A/G G/G A/A C/C G/G
20 Yes G/A T/C G/G G/G G/G A/C C/C G/T
21 Yes G/A T/C A/G A/G G/G A/A C/C G/T
22 Yes G/A T/C A/G A/G G/G A/A C/C T/T
23 Yes A/A T/T G/G G/G G/G A/A C/C T/T
24 Yes G/A T/C G/G G/G G/G A/A C/C T/T
25 Yes G/A T/T G/G G/G G/G A/A C/C G/G
26 Yes A/G T/C A/G A/G G/G ‐ ‐ ‐
Note: Samples are anonymized. Samples 1–14 are unaffected parents. Samples 15–26 are patients with GOSHS with HSCR. Sample 26 was excluded from
statistical analysis as data was not available for all SNPs.
Abbreviations: GOSHS, Goldberg–Shprintzen syndrome; HSCR, Hirschsprung disease; SNPs, single nucleotide polymorphisms.
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otherwise, as a reduction of KIFBP expression was detected for the
three variants tested (Figure 3a–c), suggesting that a threshold ex-
pression of this protein may be required for regulation of develop-
mental functions. While patient NL1 shows a mild reduction of
KIFBP expression that seems to be, to some extent, tolerable, in
patient CYP3 this threshold was not reached, leading to the typical
GOSHS phenotype. Therefore, we conclude that missense variants in
KIFBP can be as damaging as truncating variants, depending on its
effect on protein expression levels.
It has been previously noted that the diagnosis of GOSHS should
rely on molecular and genetic findings in place of phenotypic re-
cognition only, due to its similarity with other syndromes (Salehpour
et al., 2017). Based on our genetic findings, patient NL1 would be
considered to have GOSHS due to the fact that no likely pathogenic
variant has been identified in any other gene. However, this patient
has no hallmark features of GOSHS. Since locus heterogeneity is
lacking in this syndrome, and all patients with the typical features
have KIFBP variants, we believe that the accurate classification of
GOSHS based on phenotype by a clinical geneticist may be more
useful for the family to appropriately meet the needs of the patient,
as well as for advising clinical treatment.
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